Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib + asciminib in chronic myeloid leukemia resistant to ponatinib and/or asciminib
2025-521126-15-00Phase 2Authorised
- Sponsor
- Grupo Español de Leucemia Mieloide Crónica
- Start
- Jul 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib and asciminib in chronic myelogenous leukemia (CML), sponsored by Grupo Español de Leucemia Mieloide Crónica. Primary endpoint: MR2 at 6 months. Planned start Jul 2026; status: authorised.
02
Drugs
ponatinibasciminib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2025-521126-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521126-15-00.